Paul Choi
Stock Analyst at Goldman Sachs
(3.74)
# 747
Out of 5,055 analysts
114
Total ratings
54.05%
Success rate
7.63%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $75.58 | -33.84% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $66.90 | +49.48% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $41.40 | +32.85% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $11.04 | -45.65% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $52.50 | +46.67% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $22.26 | -10.15% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $42.42 | +10.80% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $16.04 | -25.19% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $23.70 | -87.34% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $2.99 | +167.56% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $14.41 | -65.30% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $40.61 | +28.05% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $5.49 | +282.51% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $12 | $11.14 | +7.72% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.82 | +6.38% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $11.14 | -10.23% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $216.56 | +3.90% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $66.95 | -10.38% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $14.73 | +28.99% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.81 | +295.01% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $8.70 | +474.71% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.42 | +1,660.56% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $8.27 | +1,955.62% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $4.96 | +61.29% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $143.56 | -5.96% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $59.58 | +403.52% | 2 | Mar 30, 2020 |
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $75.58
Upside: -33.84%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $66.90
Upside: +49.48%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $41.40
Upside: +32.85%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $11.04
Upside: -45.65%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $52.50
Upside: +46.67%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $22.26
Upside: -10.15%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $42.42
Upside: +10.80%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $16.04
Upside: -25.19%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $23.70
Upside: -87.34%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.99
Upside: +167.56%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $14.41
Upside: -65.30%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $40.61
Upside: +28.05%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.49
Upside: +282.51%
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $11.14
Upside: +7.72%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $2.82
Upside: +6.38%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $11.14
Upside: -10.23%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $216.56
Upside: +3.90%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $66.95
Upside: -10.38%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.73
Upside: +28.99%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.81
Upside: +295.01%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $8.70
Upside: +474.71%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.42
Upside: +1,660.56%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $8.27
Upside: +1,955.62%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $4.96
Upside: +61.29%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $143.56
Upside: -5.96%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $59.58
Upside: +403.52%